ArticleBMC cancer2017

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.

Emilie Lereclus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.